China’s pharmaceutical industry is transforming from a generic drug powerhouse to an innovative drug leader. In 2025, 76 Class 1 innovative drugs were approved, a year-on-year surge of 58.3%, hitting an all-time high. Nearly 3,000 new drug clinical trials were registered, with steady growth in R&D investment. Cross-border licensing-out reached 157 deals worth $135.6 billion, accounting for a substantial portion of global volume.
Supported by the revised Patent Law and Drug Administration Law, a five-pronged intellectual property (IP) protection framework covering regulatory data protection, patent term extension, patent linkage, judicial protection, and administrative enforcement has taken shape to provide solid institutional support for pharmaceutical innovations.
Regulatory data protection: fundamental safeguard for innovation
The Measures for the Implementation of Drug Regulatory Data Protection took effect on May 15 2026, offering six, four, or three years of exclusive protection for undisclosed pharmaceutical, non-clinical, and clinical data. Generic applications dependent on protected data will not be approved during the protection term, and relevant applications can only be submitted one year before expiry. As of July 18 2026, 54 drugs have obtained data protection, including 19 with a six-year term and 31 with a four-year term, which effectively fills the gaps left by patent protection alone and stabilises pharmaceutical enterprises’ long-term expectations for investment in clinical R&D.
Patent term extension: compensation for regulatory review cycles
Launched under the 2021 Patent Law, the patent term extension system grants a maximum five-year patent extension to offset time consumed by drug approval. This system precisely addresses the pain points of lengthy R&D cycles for innovative drugs and shortened effective patent protection terms, thereby mitigating risks associated with R&D investment. By July 18 2026, 32 drugs – including chemicals, biologics, and traditional Chinese medicines (TCMs) – obtained extensions, among which 24 secured the full five-year protection period, fully safeguarding the legitimate innovation returns of original drug developers.
Drug patent linkage: pre-market resolution of patent disputes
Leveraging the National Registered Drug Patent Information Platform, the patent linkage system resolves patent disputes during generic drug review, balancing innovation incentives and generic drug accessibility. As of July 18 2026, the platform contains 434 TCM entries, 1,296 chemical drug entries, and 366 biological product entries, as well as 20,881 patent declarations. Disputes are handled via dual channels of administrative adjudication and judicial litigation.
By the end of 2025, the CNIPA had accepted around 270 administrative patent linkage cases, and the Intellectual Property Tribunal of the Supreme People’s Court received 41 related appellate cases. Most disputes ended in reconciliation, avoiding large-scale post-launch infringement lawsuits.
Judicial protection: unified standards and severe sanctions
Established on January 1 2019, the Intellectual Property Tribunal of the Supreme People’s Court centrally hears national appellate cases on technical IP and monopolies, eliminating inconsistent rulings and local protection concerns. Its second-instance cases recorded a reversal rate of 20.9% and a mediation-withdrawal rate of 37.7%, better than the national average for civil second-instance cases from higher courts. Punitive damages were applied in 58 cases, with an average award of over RMB 35 million; 73 cases with damages exceeding RMB 10 million averaged nearly RMB 72 million. The Supreme People's Court released 14 typical pharmaceutical patent cases to clarify rules on crystal patents, supplementary experimental data, and generic drug infringement determination.
Administrative enforcement: maintaining market order efficiently
Local patent administrations carry out special campaigns targeting patent infringement and patent counterfeiting involving active pharmaceutical ingredients, formulations, and TCMs, with major active pharmaceutical ingredient infringement cases under key supervision. Typical enforcement cases are issued regularly to standardise infringement comparison and evidence collection.
Administrative handling shortens rights protection cycles and costs, forming a coordinated protection chain featuring rapid administrative mediation, judicial backstop, and confirmation examination, continuously regulating competition order in the pharmaceutical market.
Key takeaways
From regulatory data protection and patent term extension to pre-market dispute resolution via patent linkage, targeted judicial rulings, and efficient administrative enforcement, China has constructed a full-life-cycle closed-loop pharmaceutical IP protection system that balances incentives for original innovation and public access to medicines.
As supporting rules keep improving, the system is shifting from institutional establishment to tangible effects, driving high-quality biomedical innovation and laying a solid system foundation for building a powerful pharmaceutical country.
